A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

NCT01101464 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Asenapine 3x5mg followed by 1x15mg
DRUG: Asenapine 1x15mg followed by 3x5mg

Sponsor

Organon and Co